Severe persistent allergic asthma

被引：0

作者：

Bodzenta-Lukaszyk, Anna ^{[1
]}

Skiepko, Roman ^{[1
]}

Lenczewska, Danuta ^{[1
]}

Zietkowski, Ziemowit ^{[1
]}

机构：

[1] Wewnetrznych Uniwersytetu Med Bialymstoku, Klin Alergol & Chorob, PL-15276 Bialystok, Poland

来源：

POSTEPY DERMATOLOGII I ALERGOLOGII | 2009年 / 26卷 / 05期

关键词：

severe persistent allergic asthma; omalizumab; OMALIZUMAB; DISEASE;

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Asthma is a chronic inflammatory disease of the airways. Approximately 60% of asthma cases can be attributed to allergic asthma The aim of this article is to present the current results concerning the problem of severe persistent allergic asthma, the use of anti-IgE treatment (omalizumab) as well as our own results determining the clinical efficacy and anti-inflammatory activity of Xolair (omalizumab) in patients with severe allergic asthma.

引用

页码：329 / 330

页数：2

共 8 条

[1] Immunology of asthma and chronic obstructive pulmonary disease [J].

Barnes, Peter J. .

NATURE REVIEWS IMMUNOLOGY, 2008, 8 (03) :183-192

[2] Immunologic and inflammatory mechanisms that drive asthma progression to remodeling [J].

Broide, David H. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (03) :560-570

[3] Treating asthma as an inflammatory disease [J].

Canonica, G. Walter .

CHEST, 2006, 130 (01) :21S-28S

[4] A Population-based Clinical Study of Allergic and Non-allergic Asthma [J].

Knudsen, Thomas Bllingtoft ;

Thomsen, Simon Francis ;

Nolte, Hendrik ;

Backer, Vibeke .

JOURNAL OF ASTHMA, 2009, 46 (01) :91-94

[5] Omalizumab: overview of pharmacology and efficacy in asthma [J].

Ledford, Dennis Keith .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (07) :933-943

[6] Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma [J].

Lowe, Philip J. ;

Tannenbaum, Stacey ;

Gautier, Aurelie ;

Jimenez, Pablo .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) :61-76

[7]

Skiepko Roman, 2009, Przegl Lek, V66, P141

[8] An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma [J].

Sullivan, S. D. ;

Turk, F. .

ALLERGY, 2008, 63 (06) :670-684

← 1 →